pharmaphorum

DECEMBER 14, 2022

Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. November saw the launch of a new private equity team in life sciences at J.P. Morgan Asset Management, dubbed Life Sciences Private Capital. New CEO joins UBC.

Life Science 98

Life Science Gene Therapy Gene Editing Gene 98

pharmaphorum

SEPTEMBER 3, 2020

The area is being reimagined as a life sciences and technology hub and is already home to the Francis Crick Institute biomedical research organisation. With AI the pharma industry hopes to reduce the number of drugs that fail during the clinical development process, a huge financial drain on the industry.

Life Science 114

Life Science Scientist Engineer Pharma Companies 114

XTalks

FEBRUARY 16, 2022

In this episode, Ayesha discussed the NHS’s recommendation of Libmeldy, a gene therapy for the treatment of the rare disease MLD, which is officially the world’s most expensive drug with a list price of almost $4 million USD. New Report Finds Whopping Increase in Pharma Cybersecurity Threats.

Life Science 52

Life Science Gene Therapy Drugs Pharma Companies 52

Pharmaceutical Technology

MAY 26, 2023

Pharma company merger and acquisition (M&A) activity in the first half of 2023 has remained relatively low, consistent with the second half of last year, but investors predict deals will increase later in 2023. Experts at PWC, Goldman Sachs, and Morgan Stanley agree that pharma-related M&A is expected to pick up in 2023.

Life Science 130

Life Science Manufacturing Contract Manufacturing Gene Therapy 130

XTalks

MAY 29, 2024

The top ten pharma companies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 The top big pharma players have remained relatively consistent in their market positions over the past several years. Here is a look at the top ten pharma companies in 2024 based on 2023 revenue.

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccination 52

Cloudbyz

MAY 19, 2021

Introduction Cell and gene therapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry and is being pragmatically accepted worldwide. The gene therapy market reported its first market approvals back in 2017 and the evolution has been extensive ever since.

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

pharmaphorum

NOVEMBER 23, 2021

The DISC is the biggest investment AZ has ever made, and has been hailed by the pharma company’s chief executive Pascal Soriot as the centrepiece of what he believes could one day become a biotech hub to rival Boston and San Francisco in the US.

Gene Editing 105

Gene Editing Life Science Pharma Companies Clinical Trials 105

pharmaphorum

NOVEMBER 30, 2022

Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from life sciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine?

Life Science 98

Life Science Pharma Companies Sales Marketing 98

XTalks

DECEMBER 27, 2022

Adstiladrin is an adenoviral vector-based gene therapy that is non-replicating, so it cannot multiply in human cells. The pharma company will expand its manufacturing capacity for commercial scale vector production for oncology treatment. How Does the Gene Therapy Adstiladrin Work?

Gene Therapy 52

Gene Therapy FDA Approval Gene Clinical Trials 52

XTalks

MARCH 22, 2023

In October 2022, Xtalks celebrated two decades of bringing diverse stakeholders in the life science industry together through first holding physical events, then soon after, hosting exclusively online events. Just last year, the FDA approved a one-time gene therapy treatment for hemophilia B priced at $3.5

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

XTalks

MARCH 28, 2024

Progressive muscle weakness in the disease is caused by genetic mutations in the dystrophin gene that lead to a lack of functional dystrophin protein. Bettica said the company’s focus is to now “make Duvyzat available as a treatment for DMD management in the US as quickly as possible.” The drug generated domestic sales of $200.4

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

Pharmaceutical Technology

JANUARY 31, 2023

Inflation Reduction Act Speaking during the keynote panel “FDA & ARPA-H: Life Sciences, Biopharma & Medtech Priorities in a New Year”, Califf discussed the Inflation Reduction Act of August 2022, which aims to lower prescription drug prices. That leaves three years for pharma companies to prepare. It’s a hot area.”

Drugs 130

Drugs Gene Therapy Regulation Insulin 130

pharmaphorum

NOVEMBER 23, 2022

A director in life sciences consulting for EY, she works within the commercial space for such companies, as well as their clients. “My We looked at the areas of rare diseases, cell and gene therapy, vaccines – loads of different perspectives. Innovative offerings around market access. Smart reviewing: utilising AI and ML.

Life Science 98

Life Science Marketing Medicine Production 98

XTalks

OCTOBER 4, 2023

Heather McDonald: My previous role at Bayer was a global-level role with a specific focus on cell and gene therapies. In addition, AstraZeneca just announced a major acquisition of Pfizer’s cell and gene therapy portfolio. How is the shift toward value-based healthcare affecting drug pricing and reimbursement?

Marketing 105

Marketing Development Drugs Gene Therapy 105

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. The results also suggest further uses for the drug in early disease and more revenues to come from one of the company’s biggest success stories from the last decade.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

XTalks

OCTOBER 22, 2020

In this sense, pharmaceutical companies have developed different strategies to produce a wide variety of advanced therapy medicinal products (ATMP) and biological products, such as monoclonal antibodies, recombinant proteins, gene therapy viral vectors, CAR-T cells and oncolytic viruses, in order to deliver new medical needs in our society.

Manufacturing 98

Manufacturing Development Production Gene Therapy 98

pharmaphorum

SEPTEMBER 17, 2021

Havas Life Medicom, ARK and Pharmadoctor top the agency charts AstraZeneca, klarify and Novartis Gene Therapies top the pharma leader board. Among pharma companies and healthcare organisations, the top three companies, taking two Golds each, were AstraZeneca, klarify and Novartis Gene Therapies.

Gene Therapy 52

Gene Therapy Gene Allergies Life Science 52

XTalks

OCTOBER 15, 2021

The cell line, called HeLa, laid the foundation for many groundbreaking discoveries, including vaccines for the human papilloma virus (HPV) and polio; drugs for HIV and cancers; gene mapping; IVF treatment; and more recently, for crucial COVID-19 research. Fittingly, it was also used to develop the vaccine against cervical cancer.

Vaccination 105

Vaccination Vaccine Gene Mapping Doctor 105

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times.

Genetics 111

Genetics Vaccination Vaccine DNA 111

Delveinsight

AUGUST 4, 2021

Similarly, other companies in the domain such as Eisai/ BioArctic AB, Hoffmann-La Roche/Chugai Pharmaceuticals, Anavex Life Sciences Corp., The companies in the Parkinson’s Disease Therapeutics Market include Cortexyme, Cerevel Therapeutics, Amneal Pharmaceuticals, Pharma Two B, Cerevance, AbbVie, Theranexus, and others.

Marketing 98

Marketing Genetics Development Clinical Development 98

The Pharma Data

DECEMBER 17, 2020

Smith joined SpringWorks at the company’s inception in 2017 and was a founding member of the management team. Prior to SpringWorks, Smith was the executive vice president of Gene Therapy at Bamboo Therapeutics. Recro – CDMO company Recro announced David Enloe as its new president and CEO. based Rinri Therapeutics.

Development 52

Development Gene Therapy Engineer Life Science 52

XTalks

MAY 11, 2023

I know you also serve on the board of directors for Global Genes, which recently merged with RARE-X. Wendy: RARE-X is now the data and research arm of Global Genes, the flagship patient organization representing rare, ultra-rare, and “n-of-one” patients. I’m very committed to working in rare disease for that reason.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Development 97

pharmaphorum

OCTOBER 26, 2022

We are working to provide patients, including those living with rare diseases, with safe and effective treatments that improve their quality of life and make these treatments accessible. Every pharma company developing treatments for new diseases is contributing to some degree to better global health. About Chiesi Group.

Development 96

Development Trials Marketing Life Science 96

XTalks

APRIL 16, 2024

The drug is a calcitonin gene-related peptide (CGRP) receptor inhibitor that blocks CGRP receptors in the brain to reduce migraine symptoms of headache, nausea, vomiting, light sensitivity and sound sensitivity. Backlash against celebrities for partnering with pharma companies isn’t new.

Drugs 52

Drugs Pharma Companies Doctor Doctors 52

The Pharma Data

NOVEMBER 10, 2020

By giving companies full control of their studies, they are able to significantly speed up timelines,” Tessier said. The intricate specialties of oncology and neurology combined make up over 50% of Mispro’s client base, with immunology and gene therapy taking 14% of the pie, respectively. .

Marketing 52

Marketing In-Vivo Scientist Research 52

pharmaphorum

DECEMBER 6, 2022

The importance of health data to the life science industry is growing just as rapidly as the technology enabling its capture is advancing. It is also on target to raise additional funds of approximately £160 million from disease-related charities and from companies working within the life sciences industry.

Genome Project 98

Genome Project Research Genomics Genome 98

Pharmaceutical Technology

MAY 26, 2023

Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines. The British company’s expanded facilities boasts of 11 suites, including two class B filling suites with class A filling cabinets, warehousing and quality control laboratory capability.

DNA 130

DNA Manufacturing Gene Gene Therapy 130

Pharmaceutical Technology

APRIL 24, 2023

Biologics are costly to produce and sell, and the more recent modalities, such as cell and gene therapies, can be difficult to manufacture. With new drugs on the market, companies are now looking for ways to manufacture recently approved biologics, and countries are racing to claim their corner – or maintain their decades-old market share.

Contract Manufacturing 130

Contract Manufacturing Manufacturing Protein Sales 130

XTalks

JANUARY 6, 2025

Gene Editing CRISPR-Cas9 and related gene-editing technologies continue to advance, and today they are widely used to study and develop therapeutic approaches for a broad range of human diseases. As of March 18, 2024, the FDA has approved 36 gene therapies, with an additional 500 therapies in the pipeline.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111

XTalks

FEBRUARY 11, 2025

Gene therapy has shown promise in treating cancers that are particularly difficult to manage such as neuroblastoma and Wilms tumor using CAR-T cell therapy, CRISPR-Cas9 gene editing and RNA-based interventions to target genetic drivers of disease.

Gene Therapy 66

Gene Therapy Clinical Trials Clinical Trials Trials 66

Roots Analysis

JANUARY 27, 2025

Further, it has been observed that many pharma companies are directing their efforts towards introducing subcutaneous versions of their drugs by re-engineering and reformulating products that were initially developed for delivery via the intravenous route.

Marketing 40

Marketing Drug Delivery Development Protein 40